Abstract
The use of fixed dose combination (FDC) drug therapies has been world-widely accepted for long years due to providing better disease treatment with enhanced therapeutic efficacy and safety as well as improved patient compliance and adherence, and reduced cost to patients than single drug therapies. From many different perspectives, the development of FDC products is likely a promising approach to achieving clinical benefits and business advantages in many classes of drugs. The rationale for drug combinations can be well established only when the potential benefits are based on valid therapeutic principles and substantiated by clinical evidences. Herein, how combination products can be rationalized, individually or combinedly, with respect to category of therapeutic benefits, class of pharmacokinetic and pharmacodynamics interactions, and type of combination effects is first discussed. Potential limitations of FDC products are to be minimized through a careful assessment of benefits to risks by selecting rational component drugs and their doses as well as by either taking their efficacious interactions and/or avoiding their non-efficacious interactions. A series of step-wise product development strategies are necessary to attain target product profiles of prospective oral FDC products set based on their intended clinical use. This review gives an overview of strategies for formulation development of oral FDC products to be optimized differently depending upon prior knowledge of single products and designated dosage regimens of the FDC products, along with highlighting the current issues and challenges arising in formulation development and evaluation on the performance of FDC products.
Similar content being viewed by others
References
Abdul S, Poddar SS (2004) A flexible technology for modified release of drugs: multi layered tablets. J Control Release 97:393–405
Abebe A, Akseli I, Sprockel O, Kottala N, Cuitino AM (2014) Review of bilayer tablet technology. Int J Pharm 461:549–558
Akseli I, Dey D, Cetinkaya C (2010) Mechanical property characterization of bilayered tablets using nondestructive air-coupled acoustics. AAPS PharmSciTech 11:90–102
Bangalore S, Kamalakkannan G, Parkar S, Messerli FH (2007) Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 120:713–719
Bergmann JF (2008) Review: fixed-dose drug combinations improve medication compliance compared with free-drug regimens. Evid.-Based Med 13:18
Borghi C, Cicero AFG (2010) Rationale for the use of a fixed-dose combination in the management of hypertension. Clin Drug Investig 30:843–854
Burke MD, He X, Cook C, Petrov GA, Long S, Coffin MD (2013) Stability enhancement of drug layered pellets in a fixed dose combination tablet. AAPS PharmSciTech 14:312–320
Cahyadi C, Chan L, Colombo P, Heng P (2011) The butterfly effect: a physical phenomenon of hypromellose matrices during dissolution and the factors affecting its occurrence. Int J Pharm 406:31–40
Caspi A (2011) Clinical trials, research, and FDA findings. Biotechnol Healthc 8:10–11
Chiou WL, Jeong HY, Chung SM, Wu TC (2000) Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res 17:135–140
Choi D-H, Jeong S-H (2011) Multi-layered matrix tablets with various tablet designs and release profiles. J Pharm Investig 41:263–272
Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440–446
Chrysant SG, Melino M, Karki S, Lee J, Heyrman R (2008) The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 30:587–604
Chung M, Calcagni A, Glue P, Bramson C (2006) Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol 46:1030–1037
Dashevsky A, Kolter K, Bodmeier R (2004) Compression of pellets coated with various aqueous polymer dispersions. Int J Pharm 279:19–26
Desai D, Rao V, Guo H, Li D, Stein D, Hu FY, Kiesnowski C (2012) An active film-coating approach to enhance chemical stability of a potent drug molecule. Pharm Dev Technol 17:227–235
Desai D, Wang J, Wen H, Li X, Timmins P (2013) Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm Dev Technol 18:1265–1276
Dierickx L, Remon JP, Vervaet C (2013) Co-extrusion as manufacturing technique for multilayer mini-matrices with dual drug release. Eur J Pharm Biopharm 85:1157–1163
Dierickx L, Van Snick B, Monteyne T, De Beer T, Remon JP, Vervaet C (2014) Co-extruded solid solutions as immediate release fixed-dose combinations. Eur J Pharm Biopharm 88:502–509
Dokoumetzidis A, Macheras P (2006) A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system. Int J Pharm 321:1–11
Dubey R (2012) Bioequivalence challenges in development of fixed-dose combination products: looking beyond reformulation. Expert Opin Drug Deliv 9:325–332
Efentakis M, Peponaki C (2008) Formulation study and evaluation of matrix and three-layer tablet sustained drug delivery systems based on Carbopols with isosorbite mononitrate. AAPS PharmSciTech 9:917–923
EMA (2006) Guideline on pharmaceutical fixed combination products. European Medicines Agency, London
EMA (2015) Guideline on clinical development of fixed combination medicinal products. European Medicines Agency, London
Farnier M (2011) Safety review of combination drugs for hyperdemia. Expert Opin Drug Saf 10:363–371
FDA (2006) Guidance for industry fixed dose combinations, co-packaged drug products, and single entity versions of previously approved antiretrovirals for the treatment of HIV. Food and Drug Administration (FDA), Rockville
FDA (2015) Fixed-combination and co-packaged drugs: applications for approval and combinations of active ingredients under consideration for inclusion in an over-the-counter monograph. Proposed rule, Federal Register, 12/23/2015
Foucquier J, Guedj M (2015) Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect 3(e00149):1–11
Gautam CS, Saha L (2008) Fixed dose drug combinations (FDCs): rational or irrational: a view point. Br J Clin Pharmacol 65:795–796
Gradman AH, Basile JN, Carter BL, Bakris GL, Group ASoHW (2010) Combination therapy in hypertension. J Am Soc Hypertens 4:42–50
Haidar SH, Davit B, Chen M-L, Conner D, Lee L, Li QH, Lionberger R, Makhlouf F, Patel D, Schuirmann DJ (2008) Bioequivalence approaches for highly variable drugs and drug products. Pharm Res 25:237–241
Hainer JW, Sugg J, Vasc J (2007) Metoprolol succinate extended release/hydrochlorothiazide combination tablets. Vasc Health Risk Manag 3:279–288
Heikkinen AT, Baneyx G, Caruso A, Parrott N (2012) Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates—an evaluation and case study using GastroPlus. Eur J Pharm Sci 47:375–386
Hiremath PS, Bhonsle SA, Thumma S, Vemulapalli V (2011) Recent patents on oral combination drug delivery and formulations. Recent Pat Drug Deliv Formul 5:52–60
Ho L, Muller R, Gordon KC, Kleinebudde P, Pepper M, Rades T, Shen Y, Taday PF, Zeitler JA (2009) Terahertz pulsed imaging as an analytical tool for sustained-release tablet film coating. Eur J Pharm Biopharm 71:117–123
Honorio Tda S, Pinto EC, Rocha HV, Esteves VS, dos Santos TC, Castro HC, Rodrigues CR, de Sousa VP, Cabral LM (2013) In vitro-in vivo correlation of efavirenz tablets using GastroPlus(R). AAPS PharmSciTech 14:1244–1254
Huang L, Li F, Sheng J et al (2014) DrugComboRanker: drug combination discovery based on target network analysis. Bioinformatics 30:i228–i236
Inman SJ, Briscoe BJ, Pitt KG, Shiu C (2008) Axial tensile fracture of microcrystalline cellulose compacts. Int J Pharm 349:172–179
Ito M, Suzuki T, Yada S, Nakagami H, Teramoto H, Yonemochi E, Terada K (2010) Development of a method for nondestructive NIR transmittance spectroscopic analysis of acetaminophen and caffeine anhydrate in intact bilayer tablets. J Pharm Biomed Anal 53:396–402
Jia J, Zhu F, Ma X, Cao ZW, Li YX, Chen YZ (2009) Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8:111–128
Just S, Toschkoff G, Funke A, Djuric D, Scharrer G, Khinast J, Knop K, Kleinebudde P (2013) Optimization of the inter-tablet coating uniformity for an active coating process at lab and pilot scale. Int J Pharm 457:1–8
Kararli TT (1995) Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 16:351–380
Kararli TT, Sedo K, Bossart J (2014a) Fixed-dose combination products-A review (Part 1-introduction). Drug Dev Deliv 14(2):32–35
Kararli TT, Sedo K, Bossart J (2014b) Fixed-dose combination products-A review (Part 2-analysis). Drug Dev Deliv 14(3):28–32
Kararli TT, Sedo K, Bossart J (2014c) Fixed-dose combination products-A review (Part 3-pipeline). Drug Dev Deliv 14(4):36–39
Karim MN, Ahmed KR, Bukht MS, Akter J, Chowdhury HA, Hossain S, Anwar N, Selim S, Chowdhury SH, Hossain F, Ali L (2013) Pattern and predictors of dyslipidemia in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Clin Res Rev 7(2):95–100
Kim JY, Kim DW, Kuk YM, Park CW, Rhee YS, Oh TO, Weon KY, Park ES (2012) Investigation of an active film coating to prepare new fixed-dose combination tablets for treatment of diabetes. Int J Pharm 427:201–208
Koller DM, Hannesschlager G, Leitner M, Khinast JG (2011) Non-destructive analysis of tablet coatings with optical coherence tomography. Eur J Pharm Sci 44:142–148
Kottala N, Abebe A, Sprockel O, Akseli I, Nikfar F, Cuitino AM (2012a) Influence of compaction properties and interfacial topography on the performance of bilayer tablets. Int J Pharm 436:171–178
Kottala N, Abebe A, Sprockel O, Bergum J, Nikfar F, Cuitino AM (2012b) Evaluation of the performance characteristics of bilayer tablets: Part I. Impact of material properties and process parameters on the strength of bilayer tablets. AAPS PharmSciTech 13:1236–1242
Kuentz M (2008) Drug absorption modeling as a tool to define the strategy in clinical formulation development. AAPS J 10:473–479
Kumar V, Prasad B, Singh S (2008) Pharmaceutical issues in the development of a polypill for the treatment of cardiovascular diseases. Drug Discov Today Ther Strateg 5:63–71
Kwon KC, Lee C (2016) Analysis of fixed-dose combination products approved by the US food and drug administration, 2010-2015 implications for designing a regulatory shortcut to new drug application. Ther Innov Regul Sci 2168479016663263
LaForce C, Gentile DA, Skoner DP (2008) A randomized, double-blind, parallel-group, multicenter, placebo-controlled study of the safety and efficacy of extended-release guaifenesin/pseudoephedrine hydrochloride for symptom relief as an adjunctive therapy to antibiotic treatment of acute respiratory infections. Postgrad Med 120:53–59
Lai GH, Zhang Z, Sirica AE (2003) Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Ther 2:265–271
Liu Y, Wei Q, Yu G, Gai W, Li Y, Chen X (2014) DCDB 2.0: a major update of the drug combination database. Database bau124:1–6
Mandal U, Pal TK (2008) Formulation and in vitro studies of a fixed-dose combination of a bilayer matrix tablet containing metformin HCl as sustained release and glipizide as immediate release. Drug Dev Ind Pharm 34:305–313
Marzolini C, Gibbons S, Khoo S, Back D (2016) Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications. J Antimicrob Chemother 71:1755–1758
McConnell EL, Macfarlane CB, Basit AW (2009) An observational study on the influence of solvent composition on the architecture of drug-layered pellets. Int J Pharm 380:67–71
Migoya EM, Miller JL, Gutierrez M, Zheng W, Johnson-Levonas AO, Liu Q, Matthews CZ, Wagner JA, Gottesdiener KM (2010) Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects. Clin Drug Investig 30:855–866
Min JS, Kim D, Park JB et al (2016) Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans. Drug Des Dev Ther 10:2959–2972
Mitra A, Wu Y (2012) Challenges and opportunities in achieving bioequivalence for fixed-dose combination products. AAPS J 14:646–655
Nakatani M, Yokoyama K, Sawada T (2014) Bilayer tablet comprising telmisartan and diuretic. US Patents. 8637078
Newman J, Grobman WA, Greenland P (2008) Disease prevention in men: a decision analysis and cost-effectiveness model. Prev Cardiol 11:36–412
Nirmal J, Saisivam S, Peddanna C, Muralidharan S, Godwinkumar S, Nagarajan M (2008) Bilayer tablets of atorvastatin calcium and nicotinic acid: formulation and evaluation. Chem Pharm Bull 56:1455–1458
Niwa M, Hiraishi Y, Iwasaki N, Terada K (2013) Quantitative analysis of the layer separation risk in bilayer tablets using terahertz pulsed imaging. Int J Pharm 452:249–256
Orloff DG (2005) Fixed combination drugs for cardiovascular disease risk reduction: regulatory approach. Am J Cardiol 96:28K–33K
Pan F, Chernew ME, Fendrick AM (2008) Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 23:611–614
Panchagnula R, Kumar Bajpai A, Agrawal S, Ashokraj Y (2006) Dissolution testing of marketed rifampicin containing fixed dose combination formulations using a new discriminative media: a post marketing retrospective study. Pharmazie 61:851–854
Park J, Lee S, Kim K, Lee D (2013) Systematic approach for analyzing drug combination by using target-enzyme distance. IBC 5(3):1–7
Park HS, Han JH, Jung SH, Jo EJ, Myung CS (2016a) The combination of valsartan and ramipril protects against blood vessel injury and lowers blood pressure. J Pharm Investig 46:265–272
Park JS, Shin JH, Hong TJ et al (2016b) Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong). Drug Des Dev Ther 10:2599–2609
Pourkavoos N (2012) Unique risks, benefits, and challenges of developing drug–drug combination products in a pharmaceutical industrial setting. Comb Prod Ther 2:2–31
Pritchard JR, Bruno PM, Gilbert LA et al (2013) Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci USA 110:E170–E179
Putcharoen O, Do T, Avihingsanon A, Ruxrungtham K (2015) Rationale and clinical utility of the darunavir–cobicistat combination in the treatment of HIV/AIDS. Drug Des Devel Ther 9:5763–5769
Quintavalle U, Voinovich D, Perissutti B, Serdoz F, Grassi G, Dal Col A, Grassi M (2008) Preparation of sustained release co-extrudates by hot-melt extrusion and mathematical modelling of in vitro/in vivo drug release profiles. Eur J Pharm Sci 33:282–293
Rege BD, Gawel J, Kou JH (2002) Identification of critical process variables for coating actives onto tablets via statistically designed experiments. Int J Pharm 237:87–94
Rosenthal T, Gavras I (2006) Fixed-drug combinations as first-line treatment for hypertension. Prog Cardiovasc Dis 48:416–425
Sanz G, Fuster V (2009) Fixed-dose combination therapy and secondarycardiovascular prevention: rationale, selection of drugs and target population. Nat Rev Cardiol 6:101–110. doi:10.1038/ncpcardio1435
Sapte V (2004) Stabilized short-course chemotherapy (SCC) anti-tuberculosis drug compositions. US Patents 200502498
Serebruany VL, Malinin AI, Sane DC, Jilma B, Takserman A, Atar D, Hennekens CH (2004) Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. Eur J Pharmacol 499:315–324
Shah BM, Schafer JJ, Priano J, Squires KE (2013) Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. Pharmacotherapy 33:1107–1116
Shiyani B, Gattani S, Surana S (2008) Formulation and evaluation of bi-layer tablet of metoclopramide hydrochloride and ibuprofen. AAPS PharmSciTech 9:818–827
Sica DA (2002) Rationale for fixed-dose combinations in the treatment of hypertension. Drugs 62:443–462
Siew A (2015) Fixed-dose combinations. Pharm Technol 39(4):36–39
Sperry DC, Thomas SJ, Lobo E (2010) Dissolution modeling of bead formulations and predictions of bioequivalence for a highly soluble, highly permeable drug. Mol Pharm 7:1450–1457
The HPS2-THRIVE Collaborative Group (2014) Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371:203–212
Tiwari RV, Patil H, Repka MA (2016) Contribution of hot-melt extrusion technology to advance drug delivery in the 21st century. Expert Opin Drug Deliv 13:451–464
Tobiska S, Kleinebudde P (2003) Coating uniformity and coating efficiency in a Bohle Lab-Coater using oval tablets. Eur J Pharm Biopharm 56:3–9
Vaithiyalingam SR, Sayeed VA (2010) Critical factors in manufacturing multi-layer tablets–assessing material attributes, in-process controls, manufacturing process and product performance. Int J Pharm 398:9–13
Vynckier AK, Dierickx L, Saerens L, Voorspoels J, Gonnissen Y, De Beer T, Vervaet C, Remon JP (2014a) Hot-melt co-extrusion for the production of fixed-dose combination products with a controlled release ethylcellulose matrix core. Int J Pharm 464:65–74
Vynckier AK, Dierickx L, Voorspoels J, Gonnissen Y, Remon JP, Vervaet C (2014b) Hot-melt co-extrusion: requirements, challenges and opportunities for pharmaceutical applications. J Pharm Pharmacol 66:167–179
Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ (2009) Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 122:290–300
WHO (2003) WHO drug information 17(3):143–227
WHO (2005) WHO expert committee on specifications for pharmaceutical preparations. WHO Tech Rep Ser No. 929
Woodcock J, Griffin JP, Behrman RE (2011) Development of novel combination therapies. N Engl J Med 364:985–987
Zeeshan F, Bukhari NI (2010) Development and evaluation of a novel modified-release pellet-based tablet system for the delivery of loratadine and pseudoephedrine hydrochloride as model drugs. AAPS PharmSciTech 11:910–916
Zeeshan F, Peh KK, Tan YT (2009) Exploring the potential of a highly compressible microcrystalline cellulose as novel tabletting excipient in the compaction of extended-release coated pellets containing an extremely water-soluble model drug. AAPS PharmSciTech 10:850–857
Zhao S, Nishimura T, Chen Y et al (2013) Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med 5:206ra140
Acknowledgements
This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation funded by the Ministry of Science, ICT & Future Planning (2013M3A9B5075840) and in part by Sunchon National University Research Fund in 2015.
Conflict of interest
All authors (C. Moon and E. Oh) declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moon, C., Oh, E. Rationale and strategies for formulation development of oral fixed dose combination drug products. Journal of Pharmaceutical Investigation 46, 615–631 (2016). https://doi.org/10.1007/s40005-016-0286-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40005-016-0286-4